Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Japan Lifeline Co., Ltd.
  6. News
  7. Summary
    7575   JP3754500001

JAPAN LIFELINE CO., LTD.

(7575)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Metcela Inc. and Japan Lifeline Co., Ltd. Announces Initiation of Phase I Clinical Trial of MTC001 in Patients with Chronic Ischemic Heart Failure

07/14/2021 | 01:00am EST

Metcela Inc. and Japan Lifeline Co., Ltd. announced the start of an investigator-initiated Phase I clinical trial of MTC001 for treatment of patients with chronic ischemic heart failure. The clinical trial is conducted at the University of Tsukuba Hospital, and Metcela will be supplying MTC001. Metcela and JLL have been collaborating on multiple research projects with the University of Tsukuba Hospital in preparation for this clinical trial. Metcela is collaborating with JLL and the University of Tsukuba to bring MTC001 to the clinic. MTC001 is a combination product consisting of an autologous cell therapy and a dedicated administration catheter. Metcela has researched and developed VCAM-1-positive cardiac fibroblasts (VCF1). Fibroblasts are known for their role in scar formation and wound healing and have drawn much interest in the recent years for their critical role in heart development and maintenance of cardiac microenvironment. A specific subpopulation of fibroblasts, VCF1, has shown improvements in cardiac function in preclinical models through mechanisms related to lymphangiogenesis and cardiomyocyte proliferation, as previously reported. Patient-derived (autologous) VCF1 will be used in this clinical trial. To deliver the cell therapy, MTC001 will include a minimally invasive cell administration injection catheter, primarily developed by JLL. The catheter will be connected to the commercially available 3D mapping system to visualize the lesion site for precision cell administration.


ę S&P Capital IQ 2021
All news about JAPAN LIFELINE CO., LTD.
11/01Japan Lifeline Co., Ltd. Announces Changes in Organizations and Personnel
CI
11/01Japan Lifeline Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2022
CI
11/01Japan Lifeline Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2022
CI
09/30JAPAN LIFELINE : Notice on Acquisition of Shares of Sub-subsidiary
PU
09/30JAPAN LIFELINE : Notice on Board Resolution on Selection for TSE's New Prime Market Segmen..
PU
09/02Japan Lifeline Co., Ltd. Announces Changes in Organizations, Effective on October 1, 20..
CI
09/02Japan Lifeline Co., Ltd. Announces Changes in Personnel, Effective on October 1, 2021
CI
08/04JAPAN LIFELINE : Summary Report of Consolidated Financial Results for the Three Months End..
PU
08/04Japan Lifeline Co., Ltd. Provides Year End Cash Dividend Guidance for the Year Ending M..
CI
08/04Japan Lifeline Co., Ltd. Provides Earnings Guidance for the Six Months Ending September..
CI
More news
Financials
Sales 2022 52 886 M 465 M 465 M
Net income 2022 7 882 M 69,3 M 69,3 M
Net cash 2022 7 581 M 66,7 M 66,7 M
P/E ratio 2022 11,3x
Yield 2022 3,32%
Capitalization 89 106 M 783 M 784 M
EV / Sales 2022 1,54x
EV / Sales 2023 1,35x
Nbr of Employees 1 167
Free-Float 68,2%
Chart JAPAN LIFELINE CO., LTD.
Duration : Period :
Japan Lifeline Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAPAN LIFELINE CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 1 108,00 JPY
Average target price 1 583,33 JPY
Spread / Average Target 42,9%
EPS Revisions
Managers and Directors
Keisuke Suzuki President & Representative Director
Takeshi Egawa Manager-Accounting & Finance
Yumiko Hoshiba Director & Senior Manager-Personnel
Kenji Yamada MD, GM-Administration & Head-Corporate Planning
Fumihiro Sasaki Independent Outside Director
Sector and Competitors